Lokon Pharma AB, a company developing next-generation cancer therapeutics, has selected Biovian Oy as a CDMO partner for GMP manufacturing of LOAd703 for a pivotal randomized study. The uniquely engineered LOAd703 oncolytic virus is currently …
The leading regional newspaper of of the Southwest Finland interviewed Knut Ringbom, the CEO of Biovian about the COVID-19 vaccine manufacturing possibilities. “Pandemic vaccine manufacturing is a hot topic. We have been contacted by European …
GEN, one of the biggest biotech magazines interviewed Biovian about the critical bottlenecks in Adeno-associated virus (AAV) Manufacturing. AAVs, gene therapy and manufacturing technologies are two of the “hottest” biotech areas in the industry right …
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely critical. In this roundtable discussion, …
The article discusses the challenges small and mid-sized companies are facing when taking AAV vector-based innovations from the laboratory bench to the clinic. While in-house manufacturing may be an option for some companies, partnering with a …
Affibody AB, a Swedish biotech company focused on developing next-generation biopharmaceuticals has selected Biovian Oy, the leading Nordic One-Stop-Shop CDMO for biopharmaceuticals as a CDMO partner for ABY-062 recombinant protein for clinical trial use. The …
We are pleased to let you know that Magnus Gustafsson from Biovian will speak about New Biologicals at “New Horizons in Biologics & Bioprocessing digital event”, on December 17th at 8:45 (CET). TALK: Manufacture and …
Discussion with Outi Heikkilä, PhD in Virus Interaction and Tuomas Nikula, PhD in Medical Biochemistry and Genetics. The goal of gene therapy is to treat or cure severe diseases by carrying genetic material to the …
To display how Finland and Finnish solutions participate in the fight against cancer, Business Finland has compiled a new digital booklet, providing an overview of the extensive know-how and current areas of innovation. Biovian’s CDMO …
A conversation with Pirjo Merilahti, PhD., Virology. At Biovian, Viral Vector process development is planned and executed by a team of experienced scientists, led by Dr Pirjo Merilahti. Her team typically starts the project with …
